Latest Trading on NASDAQ

Open 219.31
Previous Close 219.28
Today's Range
218.60 219.54
52 Week Range
87.07 219.57
Volume 1.46M
Avg. Volume (Weekly) 743.32K
Bid 0.00
Ask 0.00
Market Cap 6.86M
EPS -1.81
Shares Outstanding 31.35K
YTD High 219.57
Updated March 18, 2020

GW Pharmaceuticals PLC Sponsored ADR

U.K.-based GW Pharmaceuticals (“GW Pharma”) was formed in 1998 to develop cannabinoid based drugs. Much of its research and development efforts are focused on treatments for rare conditions stemming from epilepsy, glioma (a form of brain tumor), and schizophrenia.

No data to display.

GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.